RESTON, Va.Ralph Becker, mayor of Salt Lake City, Utah, has issued an official proclamation declaring June 5-9 "Molecular Imaging Days," coinciding with SNM's 57th Annual Meetingone of the world's largest events focusing exclusively on fulfilling the educational and networking needs of the molecular imaging and therapy community.
"This is the first time that we have held our meeting in Salt Lake City," said Michael M. Graham, Ph.D., M.D., president of SNM. "Meeting attendees will have an opportunity to experience a beautiful city as they learn about advances in the field of molecular imaging to improve patient care."
SNM's Annual Meeting will bring together more than 6,000 members of the molecular imaging and nuclear medicine community, including physicians, technologists, scientists, physicists and pharmacists, to learn and share research about advances in the practice of molecular imaging and therapy.
Peter Herscovitch, M.D., chair of the scientific program committee, said, "There is no other event this large for nuclear medicine and molecular imaging scientists and practitioners. A top-notch educational and scientific program, exceptional networking opportunities and an attractive destination are just a few of the reasons why this year's meeting is a must-attend."
Annually, more than 20 million men, women and children undergo safe, noninvasive molecular imaging procedures with state-of-the-art imaging technologiesincluding PET and SPECT scansto "photograph" biological targets or pathways in the body to help diagnose and treat disease and to evaluate how well treatment is working.
Molecular imaging is at the forefront of "personalized medicine" by providing patient-specific information that allows tailored treatment of disease. It is helping to advance the understanding, diagnosis, treatment and follow-up of cancer, cardiovascular disease and neurological disorders to improve the lives of people worldwide.
The mayor calls on all residents of the community to understand the benefitshistorical, current and futureof molecular imaging and therapy.
|Contact: Amy Shaw|
Society of Nuclear Medicine